drugset / Trial / NCT00233337

Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers

NCT00233337 ↗

Phase 4 Completed Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of co-artemether in the treatment of acute uncomplicated P. falciparum malaria in returning non-immune travellers THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Timeline

Start
2001-05
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Co-artemether Unknown — —